Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review
Sudha Rajagopal(Trillium Health Centre), Teresa M. Petrella, A. Sun(University of Toronto), Xiaomei Yao(Shanxi Medical University), Frances C. Wright(Saint John's Health Center), Alexandra Easson(Princess Margaret Cancer Centre), Carolyn Nessim(University of Ottawa), Tara Baetz(Queen's University), Wadid Abadir(Sunnybrook Health Science Centre), Elaine McWhirter(Juravinski Cancer Centre), Gregory Knight(Grand River Hospital), Cheryl F. Rosen(University Health Network)
Cited by 6
Related Papers
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
|Military Medical Research|2020|2.4k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
|The Lancet|2017|1.2k
A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale
|International Journal of Cancer|2020|474